AngioSoma Showcases New Product at Bodybuilding Event

New StemStrength™ Deluxe Available at NPC Texas Legends Championships

HOUSTON–AngioSoma (OTC: SOAN), a leading biotechnology research and development company, announces today they will be attending and exhibiting at the NPC Texas Legends Championships bodybuilding competition in Dallas, Texas this coming Saturday, October 27, 2018.

SomaCeuticals, makers of the new StemStrength™ Deluxe and subsidiary of AngioSoma, Inc., will be featuring its recently launched StemStrength™ Deluxe, a natural nutraceutical, delivered in capsule form, is engineered to provide energy, focus, accelerated fat loss, and more rapid muscle gain, among many other benefits.  Designed to be taken in the morning and before bed for maximum effect, StemStrength™ represents a complete solution for Women and Men looking for an edge in their workouts or daily life.  The morning formula excels at creating energy, focus and power for the day’s work ahead. The evening formula maximizes recovery and promotes a restful sleep.

“StemStrength™ Deluxe is not just for bodybuilders,” said Alex Blankenship, President. “This new formulation enhances people’s lives, regardless of activity level, and maximizes the results you get from workouts.  With the AM and PM regimen, StemStrength™ Deluxe is a gamechanger.”

View products on Amazon.com:  Go to Amazon Now

Our products can also be found on our ecommerce site: YouthfulBrilliance.com.

ABOUT ANGIOSOMA, INC.

AngioSoma, Inc. (https://angiosoma.com), a Nevada corporation based in Houston, Texas, is dedicated to improving the mental and physical wellbeing of men and women. To accomplish that purpose, we are launching a line of supplements under our SomaCeuticals™ common identity. Our supplements cover three industry segments: nutraceuticals, cosmeceuticals, and pharmaceuticals.

NOTICE REGARDING FORWARD LOOKING STATEMENTS

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.

Contacts

AngioSoma, Inc.
Alex Blankenship
investors@AngioSoma.com